Tenderwize
Retour à la recherche

Discount Agreement for Natalizumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Oct 03, 2027 · 400 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Natalizumab in der Darreichungsform Konz.z.Herst.e.Inf.-Lsg. , ATC L04AG03

50/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

50 / 100

Facteurs de risque

No estimated value or volume commitment means the financial opportunity is uncertain. Discount agreements may result in...

Contracts can be automatically terminated if other discount agreements (formal tender) come into effect. This introduce...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Provision of pharmaceutical products containing the active substance Natalizumab in the dosage form 'Konz.z.Herst.e.Inf.-Lsg.' (concentrate for solution for infusion).
  • Non-exclusive discount agreements under § 130a Abs. 8 SGB V with AOK Bayern.
Afficher le résumé complet

This is an open-house model for non-exclusive discount agreements (Rabattverträge) for the active substance Natalizumab (ATC L04AG03) in the dosage form 'Konz.z.Herst.e.Inf.-Lsg.' (concentrate for solution for infusion). The AOK Bayern intends to conclude identical, non-negotiable discount agreements with all interested pharmaceutical companies that meet the eligibility criteria. The procedure is not subject to procurement law and does not involve a selection. Contracts can be concluded at any time until 03.10.2027, with earliest start on 01.12.2025 and end on 30.11.2027. There is one lot covering all pharmaceutical products with the specified substance. No estimated value is provided.

Risques

No estimated value or volume commitment means the financial opportunity is uncertain. Discount agreements may result in...

Contracts can be automatically terminated if other discount agreements (formal tender) come into effect. This introduce...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible to participate.

Administrative

  • Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission of signed contract and annex listing the pharmaceutical products.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; non-selective open-house model.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Discount Agreement for Natalizumab

Non-exclusive discount agreements for the active substance Natalizumab in the specified dosage form, ATC L04AG03. Contracts are open to all eligible pharmaceutical companies.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Nov 2025 - Nov 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; non-selective open-house model.

Date limite

Deadline Oct 03, 2027

Détails de la procédure

Date de publication
13 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
673381-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30